Pulmonary arterial hypertension and Paranasal sinus hypersecretion
Paranasal sinus hypersecretion is found among people with Pulmonary arterial hypertension, especially for people who are female, 60+ old.
The study analyzes which people have Paranasal sinus hypersecretion with Pulmonary arterial hypertension. It is created by eHealthMe based on reports of 183 people who have Pulmonary arterial hypertension from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
183 people who have Pulmonary Arterial Hypertension and Paranasal Sinus Hypersecretion are studied.
What is Pulmonary arterial hypertension?
Pulmonary arterial hypertension (high blood pressure in the arteries of lungs) is found to be associated with 1,238 drugs and 761 conditions by eHealthMe.
What is Paranasal sinus hypersecretion?
Paranasal sinus hypersecretion is found to be associated with 740 drugs and 395 conditions by eHealthMe.
Number of Paranasal sinus hypersecretion in Pulmonary arterial hypertension reports submitted per year:
Gender of people who have Pulmonary arterial hypertension and experienced Paranasal sinus hypersecretion *:
Age of people who have Pulmonary arterial hypertension and experienced Paranasal sinus hypersecretion *:
Common co-existing conditions for these people *:
Common drugs taken by these people *:
Common symptoms for these people *:
* Approximation only. Some reports may have incomplete information.
Do you take medications and have Paranasal sinus hypersecretion?Check whether Paranasal sinus hypersecretion is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Hung YM, Cheng CC, Wann SR, Lin SL, "Ankylosing spondylitis associated with pulmonary arterial hypertension", Internal Medicine, 2016 Jan .
Treatments, associated drugs and conditions:
COVID vaccines that are related to Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion in Moderna COVID Vaccine
- Paranasal sinus hypersecretion in Pfizer BioNTech Covid Vaccine
- Paranasal sinus hypersecretion in Johnson and Johnson Covid Vaccine
Common drugs associated with Paranasal sinus hypersecretion:
- Enbrel: 868 reports
- Humira: 569 reports
- Methotrexate: 292 reports
- Prednisone: 275 reports
- Aspirin: 232 reports
- Repatha: 158 reports
- Lisinopril: 147 reports
- Omeprazole: 129 reports
- Vitamin d: 128 reports
- Synthroid: 127 reports
All the drugs that are associated with Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion (740 drugs)
Common conditions associated with Paranasal sinus hypersecretion:
- Rheumatoid arthritis: 887 reports
- Psoriasis: 271 reports
- High blood cholesterol: 221 reports
- Primary pulmonary hypertension: 183 reports
- Multiple sclerosis: 149 reports
- Crohn's disease: 146 reports
- High blood pressure: 139 reports
- Osteoporosis: 135 reports
- Asthma: 108 reports
All the conditions that are associated with Paranasal sinus hypersecretion:
- Paranasal sinus hypersecretion (395 conditions)
How the study uses the data?
The study is based on Paranasal sinus hypersecretion and Pulmonary arterial hypertension, and their synonyms.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Valproic Acid and Tremor - 7 seconds ago
- Henoch-Schonlein Purpura and drugs of ingredients of amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate - 14 seconds ago
- Vistaril and Quinapril Hydrochloride drug interaction - 19 seconds ago
- Allegra D 24 Hour vs. Children'S Zyrtec Allergy - 21 seconds ago
- Rabeprazole and Acute Coronary Syndrome - 21 seconds ago
- Simethicone and Zemplar drug interaction - 23 seconds ago
- Apidra and Hereditary Angioedema - 24 seconds ago
- Cephalexin and Acetylcarnitine drug interaction - 24 seconds ago
- Fluoxetine Hydrochloride vs. Tramadol Hydrochloride - 28 seconds ago
- Iressa and Joint Pain - 31 seconds ago